USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
CUMBERLAND PHARMACEUTICALS, INC.
Address:
CUMBERLAND PHARMACEUTICALS INC.
2525 WEST END AVE, STE 950
NASHVILLE, TN 37203
Phone:
N/A
URL:
N/A
EIN:
621765329
DUNS:
69532880
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
STTR Phase I $343,977.00 3
STTR Phase II $749,143.00 1

Award List:

High Purity Amphotericin B: A Safer Antimycotic in AIDS

Award Year / Program / Phase:
2005 / STTR / Phase I
Award Amount:
$110,644.00
Agency:
HHS
Principal Investigator:
Research Institution:
UNIVERSITY OF MISSISSIPPI
RI Contact:
N/A
Abstract:
DESCRIPTION (provided by applicant): Cumberland Pharmaceuticals and the University of Mississippi Mycotic Research Centers' long-term goal will be to improve anti-fungal pharmacotherapy particularly for patients with human immunodeficiency infections (HIV). We are jointly developing a high purity… More

Radioprotection by use of Topical Lithium Formulations

Award Year / Program / Phase:
2009 / STTR / Phase I
Award Amount:
$121,528.00
Agency:
HHS
Principal Investigator:
Research Institution:
VANDERBILT UNIVERSITY
RI Contact:
N/A
Abstract:
DESCRIPTION (provided by applicant): Roughly 500,000 cancer patients are treated with radiotherapy each year. Acute and late sequelae of radiotherapy have a negative impact upon the quality of life of cancer survivors. These sequelae include proctitis, cys titis, esophageal stricture, cutaneous… More

Mannan, A Potential Therapeutic for Asthma

Award Year / Program / Phase:
2009 / STTR / Phase I
Award Amount:
$111,805.00
Agency:
HHS
Principal Investigator:
Research Institution:
UNIVERSITY OF TENNESSEE HEALTH SCI CTR
RI Contact:
N/A
Abstract:
DESCRIPTION (provided by applicant): The long-term goal of this application is to develop mannan derived from Baker's yeast as asthma therapy. The limitations of currently available immunomodulators are their toxicity at higher doses and the lack of benefi cial effect on airway smooth muscle (ASM)… More